Azenta, Inc. (AZTA) vs Generate Biomedicines, Inc. (GENB)
A side-by-side comparison of Azenta, Inc. and Generate Biomedicines, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AZTA
Azenta, Inc.
$39.89HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
GENB
Generate Biomedicines, Inc.
$14.16HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — AZTA vs GENB
growth of $100 · dividends reinvested · last 1yAZTA +53.3% (+53.3%/yr)GENB +10.0% (+10.0%/yr)AZTA compounded faster over this window
AZTA GENB
AZTA vs GENB: by the numbers
- •AZTA is the larger company ($1.84B vs $1.82B market cap).
- •Both run net losses; AZTA's is the smaller (-20.02% vs -636.99% net margin).
Metrics side by side
Valuation
| Metric | AZTA | GENB |
|---|---|---|
| Forward P/E | 80.31 | N/A |
| P/S ratio | 3.00 | N/A |
| P/B ratio | 1.22 | 3.98 |
| EV / EBITDA | 49.74 | N/A |
| FCF yield | 0.54% | N/A |
Profitability
| Metric | AZTA | GENB |
|---|---|---|
| Gross margin | 44.05% | 100.00% |
| Operating margin | -3.49% | -737.04% |
| Net margin | -20.02% | -636.99% |
| ROE | -8.14% | N/A |
| ROIC | -1.33% | -94.79% |
Growth (annualized)
| Metric | AZTA | GENB |
|---|---|---|
| Revenue CAGR (5Y) | 4.82% | N/A |
| Total return CAGR (5Y) | -15.91% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.